Human Anti-Estrogen Receptor, alpha (Marker of Estrogen Dependence) Antibody Product Attributes
Estrogen Receptor, alpha (Marker of Estrogen Dependence) Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ESR1 antibody staining is expected to be primarily localized to the nucleus and vesicles.
Observed Antibody Staining Data By Tissue Type:
Variations in Estrogen Receptor antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the endometrial stroma in endometrium, glandular cells in the cervix, uterine, endometrium and fallopian tube, squamous epithelial cells in the cervix and uterine. More moderate antibody staining intensity was present in cells in the endometrial stroma in endometrium, glandular cells in the cervix, uterine, endometrium and fallopian tube, squamous epithelial cells in the cervix and uterine. Low, but measureable presence of Estrogen Receptor could be seen insmooth muscle cells in the smooth muscle. We were unable to detect Estrogen Receptor in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Estrogen Receptor expression as measured by anti-Estrogen Receptor antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal Intensity | +++ | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
ESR1 Variability | ++ | ++ | + | + | ++ | + | + | + | + | + | + | ++ | + | + | + | + | + | + | + | + |
Estrogen Receptor, alpha (Marker of Estrogen Dependence) General Information | |
---|---|
Alternate Names | |
Estrogen Receptor alpha delta 4*5,6,7*/654 isoform; Estrogen Receptor alpha delta 4 +49 isoform; Nuclear receptor subfamily 3 group A member 1 | |
Molecular Weight | |
~67kDa | |
Chromosomal Location | |
Ships on blue ice. | |
Curated Database and Bioinformatic Data | |
Gene Symbol | 2099 |
Entrez Gene ID | ESR1 |
UniProt ID(s) | P03372 |
UniGene ID(s) | Hs208124 |
COSMIC ID Link(s) | ESR1 |
KEGG Gene ID(s) | hsa:2099 |
General Description of Estrogen Receptor, alpha (Marker of Estrogen Dependence). | |
This monoclonal antibody is specific to estrogen receptor alpha (ER alpha) and shows minimal cross-reaction with other members of the family. ER is an important regulator of growth and differentiation in the mammary gland. Presence of ER in breast tumors indicates an increased likelihood of response to anti-estrogen (e.g. tamoxifen) therapy. It strongly stains nuclei of epithelial cells in breast carcinomas. |
There are no reviews yet.